Skip to main content
SpringerLink
Log in

Chemosensitivity of malignant human brain tumors

Preliminary results

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Tumor cell proliferation and morphological changes in tumor cells under the influence of different cytostatic agents were measured in an in vitro assay to determine chemosensitivity of human malignant brain tumors. Aliquots of 2 to 5 × 104 cells of a tumor cell suspension (prepared from biopsy specimen by mechanical and enzymatic disintegration) were incubated for 72 hr in the presence of different cytostatic agents. After another nine days of incubation in fresh medium, cell proliferation was calculated by incorporation of 14C-leucine and 3H-uridine and measurement in a liquid scintillation counter. Morphological changes in tumor cells were evaluated in Labtek tissue culture slides cultured under identical conditions. All drugs were tested in pharmacologically achievable concentrations. In vitro BCNU-sensitivity of 7/17 patients correlated with a postoperative recurrence free interval of 15.1 months, in vitro BCNU-resistance of 10/ 17 patients correlated with a postoperative recurrence free interval of 6.38 months (p < 0.001). Tumors of lower grades of malignancy (astrocytoma III, malignant ependymoma, medulloblastoma) in our series have a statistically significant higher median BCNU-sensitivity (63.5%, p < 0.05) and are sensitive to more drugs (3.6 drugs, median out of six selected drugs, p < 0.01) than tumors of higher grades of malignancy (astrocytoma IV, glioblastoma multiforme; 29.54% BCNU-sensitivity, 1.4 effective drugs). In our series differences of BCNU-tumor sensitivity and number of effective drugs were not statistically significant if related to age and sex of tumor bearing patients. We think this assay provides the opportunity to test a large number of drugs in a very short period of time. Results may indicate alternative drug regimen for those patients resistant to conventional chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alberts BS, Chen HGS, Liu R: Bleomycin pharmacokinetics in man. I. Intravenous administration. Cancer Chemother Pharmacol 1:117–181, 1978.

    Google Scholar 

  2. Avellanosa AM, West CR, Tsukada Y, Higby DO, Barshi S, Reese PA, Jennings E: Chemotherapy of nonirradiated malignant gliomas. Cancer 44:839–846, 1979.

    Google Scholar 

  3. Begemann H, Rastetter J: Atlas der klinischen Hämatologie. Springer Verlag, Berlin, Heidelberg, New York, 1978, pp 9–24.

    Google Scholar 

  4. Bergevin PR, Thormey DC, Blom J: Cancer chemotherapeuticagents. In: Bergevin PR, Blom J, Thorney D(eds) Guide to therapeutic oncology. Williams & Wilkins, Baltimore, London 1979, pp 99–161.

    Google Scholar 

  5. Bigner DD, Bourdon MA, Pegram CN, Eng LF, Coleman RE, Wikstrand CJ: Lokalization of glioma-associated antigens at the cellular, tissue, and whole body level with monoclonal antibodies. Workshop on monoclonal antibodies against gliomas and other neuroectoderm derived tumors. De Tribolet, Lausanne, 1982.

  6. Bigner DD, Bullard D, Schold C, Preissig SH, Wikstrand CJ: Cellular heterogeneity and diversity as a basis for therapeutic resistance of human gliomas. In: Paoletti P, Walker MD, Butti, G, Knerich R (eds) Multidisciplinary aspects of brain tumor therapy. Elsevier/North-Holland, Amsterdam, 1979, pp 329–335.

    Google Scholar 

  7. Billiau A, DeSomer P, Gedy VP, DeClerque E, Heremans H: Human fibroblast interferon for clinical trials: Pharmacokinetics and tolerability in experimental animals and humans. Antimicrob Agents Chemother 16: 56–63, 1979.

    Google Scholar 

  8. Bloom HJG: Prospects for increasing survival in children with medulloblastoma: Present and future studies. In: Paoletti P, Walker MD, Butti G, Knerich R (eds) Multidisciplinary aspects of brain tumor therapy. Elsevier/North-Holland, Amsterdam, 1979, pp 245–261.

    Google Scholar 

  9. Breithaupt H, Pralle H, Löffler H: Behandlung refraktärer Leukosen mit hochdosiertem Cytarabin. Blut 41:295–298, 1980.

    Google Scholar 

  10. Broder LE, Rall DP: Chemotherapy of brain tumors. Proc Exp Tumor Res 17:373–399, 1972.

    Google Scholar 

  11. Brooks WH, Netzky MG, Normansell DE: Depressed cellmediated immunity in patients with primary intracranial tumors. J Exp Med 136:1631–1647, 1972.

    Google Scholar 

  12. Chabner BA, Myers CE: Clinical pharmacology of cancer chemotherapy In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and practice of oncology. Lippincott Comp, Philadelphia, Toronto, 1982, pp 155–197.

    Google Scholar 

  13. Chen TT, Mealey J: Effects of cytosine arabinoside and 1,3-bis (2-chloroethyl)-1-nitrosourea on human glial tumor cells. Cancer Res 32:558–564, 1972.

    Google Scholar 

  14. Creaven PJ, Allen LM: Epeg: A new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 18:221–226, 1975.

    Google Scholar 

  15. Eng LF: Brain related antigens. In: Thomas DGT (ed) Brain tumors. Butterworth, London, 1980, pp 109–121.

    Google Scholar 

  16. Freshney LE: Tissue culture of glioma of the brain. In: Thomas DGT, Graham DE (eds) Brain tumors: scientific basis, clinical investigation and current therapy. Butterworth, London, Boston, 1981, pp 21–50.

    Google Scholar 

  17. Göbel U, Kauther K, Seibert H, Jürgens J, Bock W: Kombinationstherapie bei Kindern mit rezidivierenden Hirntumoren mit hochdosiertem Methotrexat, Citrovorum Faktor Rescue (CRF) and COPP. Deutscher Krebskongress, München, 1982 (in press).

  18. Hilfenhaus J, Damm H, Karges HE, Manthey KF: Growth inhibition of human lymphoblastoid daudi cells in vitro by interferon preparations. Arch Virol 51:87–97, 1976.

    Google Scholar 

  19. Ho DHW, Frei E: Clinical pharmacology of 1-\-D-arabino-furanosyl cytosine. Clin Pharmacol Ther 12:944–954, 1971.

    Google Scholar 

  20. Hoshino T: The cell kinetics of gliomas: its prognostic value and therapeutic implications. In: Paoletti P, Walker MD, Butti G, Knerich R (eds) Multidisciplinary aspects of human brain tumor therapy. Elsevier/ North-Holland, Amsterdam, 1979, pp 105–113.

    Google Scholar 

  21. Jellinger K, Volc D, Podreka I, Grisold W, Flament H: Ergebnisse der Kombinationsbehandlung maligner Gliome. Nervenarzt 52:41–50, 1981.

    Google Scholar 

  22. Jellinger K, Kothbauer P, Volc D, Volmer R, Weiss R: Combination chemotherapy (COMP protocol) and radiotherapy of anaplastic supratentorial gliomas. Acta Neurochir 51:1–13, 1979.

    Google Scholar 

  23. Kanno T, Kudo T, Nakazawa T: Anti-brain tumor activity of bleomycin. Rinshu Shinheigaku (Clin Neurol) 10:409–414, 1970.

    Google Scholar 

  24. Khan A, Mc Cullogh D, Borts F, SinksLF: Update on the use of Cisplatinum in CNS malignancies (abstract). ASCO Abstr 3:390, 1980.

    Google Scholar 

  25. Kornblith PL, Barry HS, Leonhard LA: Response of cultured human brain tumors to nitrosoureas. Correlation with clinical data. Cancer 47:255–265.

  26. Kornblith PL, Quindlen EA, Pollock LA, Coakham HB: Humoral immunology of brain tumors. In: Paoletti P, Walker MD, Butti G, Knerich R (eds) Multidisciplinary aspects of brain tumor therapy. Elsevier/North-Holland, Amsterdam, 1979, pp 113–123.

    Google Scholar 

  27. Krauseneck P, Schmidt W, Lorenz R: Treatment of inoperable supratentorial gliomas with radiation, BCNU, and bleomycin. A multicenter trial (abstract). 12th World Congress Neurology, Kyoto, Japan. Excerpta Medica, Amsterdam, 1981, pp 301.

    Google Scholar 

  28. Kumar ARV, Renaudin J, Wilson CB, Boldrey E, Enot KJ, Levin VA: Procarbazine hydrochloride in the treatment of brain tumors. J Neurosurg 40:365–371, 1974.

    Google Scholar 

  29. Levin VA: Current trends in brain tumor therapy. In: Paoletti P, Walker MD, Butti G, Knerich R (eds) Multidisciplinary aspects of brain tumor therapy. Elsevier/North-Holland, Amsterdam, 1979, pp 165–173.

    Google Scholar 

  30. Levin VA, Pokar M, Kabra M, Freman-Dove MA: Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. J Neurosurg 48:587–593, 1978.

    Google Scholar 

  31. Lumbsden CE: The sturdy by tissue culture of tumors of the nervous system. In: Russel DS, Rubinstein J (eds) Pathology of tumors of the nervous system. Edward & Arnold, London, 1971, pp 334.

    Google Scholar 

  32. Mealey J, Chen TT, Shupe R: Response of cultured human glioblastomas to radiation and BCNU chemotherapy. J Neurosurg 41:339–349, 1974.

    Google Scholar 

  33. Nagai M, Arai T: Interferon as a treatment for malignant brain tumors (abstract). In: Neurological surgery, abstracts of the 7th International Congress, Munich, 1981 pp 365.

  34. Patten TF, Himmelstein KJ, Belt R: Plasma levels and urinary excretion of filterable platinum species following bolus injection and LV. infusion of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 63:1359–1361, 1979.

    Google Scholar 

  35. Poisson M, Pouillart P, Bataini JP, Mashaly R, Pertuiset BF, Metzger J: Malignant gliomas treated after surgery by combination chemotherapy and delayed irradiation. Acta Neuroch (Wien) 51:15–25, 1979.

    Google Scholar 

  36. Rosenblum ML, Dougherty DA, Deen DF, Hoshino T, Wilson CBL: Analysis of clonogenic human brain tumor cells: Preliminary results of tumor sensitivity testing with BCNU. Br J Cancer 41:181–185, 1980.

    Google Scholar 

  37. Rosenblum ML, Dougherty DV, Barger GR, Levin VA: Age-related chemosensitivity of stem-cells from human malignant brain tumors. Lancet 4:885–887, 1982.

    Google Scholar 

  38. Sano K, Shitara N, Takakura K: Interferon productivity of human lymphocytes with the induction of poly-I-C in cases of malignant glioma. In: Specialized neurosurgical techniques. Springer, Berlin 1979, pp 376–381.

    Google Scholar 

  39. Shapiro WR, Young DF: Treatment of malignant glioma Arch Neurol 33:494–500, 1976.

    Google Scholar 

  40. Shapiro WR, Allen JC, Mehta B, Blasberg RG, Kobayashi T, Patlak CS: Pharmacodynamics of entry of methotrexate into brain of humans, monkeys, and rat brain tumor model. In: Paoletti P, Walker MD, Butti G, Knerich R (eds) Multidisciplinary aspects of brain tumor therapy. Elsevier/NorthHolland, Amsterdam, 1979, pp 135–143.

    Google Scholar 

  41. Sklansky BD, Mann-Kaplan RS, Reynolds AF, Rosenblum ML, Walker MD: 4′-dimethylepipodophyllotoxin-\-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms, Cancer 33:460–471, 1974.

    Google Scholar 

  42. Steel GG: Growth kinetics of brain tumors. In: Thomas DGT, Graham DE (eds) Brain tumors: scientific bais, clinical investigation and current therapy. Butterworth, London, Boston, 1981, pp 10–20.

    Google Scholar 

  43. Stewart DJ, Leavens M, Luna M, Seifert W, Loo TL, Benjamin RS: Human central nervous system pharmacology of cis-diamminedichloroplatinum (DDP). ASCO Abstr 3:359, 1981.

    Google Scholar 

  44. Sullivan MP, Eys J, Herson J, Starling KA, Ragab A, Sexhaner C: Nonresponsiveness of brain tumors to VM26 therapy in children. Cancer Treat. Rep 63:155–159, 1979.

    Google Scholar 

  45. Sweet DL, Hendler FJ, Handlon K, Hekmatpanah J, Griem M, Duda E, Mulligan B, Wollman R: Treatment of grade III and IV astrocytoma with BCNU alone and in combination with VM26 following surgery and radiation therapy. Cancer Treat Rep 63:1707–1711, 1979.

    Google Scholar 

  46. Takeuchi K: Effect of bleomycin on brain tumors. Gann Monogr Cancer Res 19:117–132, 1976.

    Google Scholar 

  47. Thomas DGT, Darling JL, Freshney RI, Morgan D: In vitro chemosensitivity assay of human glioma by scintillation autofluorography. In: Paoletti P, Walker MD, Butti G, Knerich R (eds) Multidisciplinary aspects of brain tumor therapy. Elsevier/North-Holland, Amsterdam, 1979, pp 19–35.

    Google Scholar 

  48. Treuner J, Dannecker G, Joester KE, Hettinger A, Niethammer D: Pharmacological aspects of clinical stage I/II trials with human beta-interferon in children. J Interferon Res 1:373–380, 1981.

    Google Scholar 

  49. Trouillas P: Immunotherapy of cerebral tumors. In: Thomas DGT (ed) Brain tumors. Butterworth, London, 1980, pp 359–371.

    Google Scholar 

  50. Ueda S, Fujimoto M, Hirakawa K, Nakagawa Y, Suzuki K: Interferon therapy for brain tumor patients. Abstracts of the 7th International Congress Neurological Surgery, 1981, Munich, pp 365.

  51. Walker MD, Alexander E Jr, Hunt WE, McCarty CS, Mahaley MS, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333–356, 1978.

    Google Scholar 

  52. Wilson CB: Single agent chemotherapy of brain tumors. Arch Neurol 33:739–747, 1976.

    Google Scholar 

  53. Yamamoto H, Takakura K, Shitara N, Sano K: Recruitment —chemo-radiotherapy with VM 26 (epipodophyllotoxin) for induction treatment of malignant brain tumors. Acta Neurochir [Suppl] (Wien) 28:616–618, 1979.

    Google Scholar 

  54. Young HF, Sakalas R, Kaplan AM: Inhibition of cell-mediated immunity in patients with brain tumors. Surg Neurol 5:19–23, 1976.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurological Department, University of Wurzburg, Federal Republic of Germany

    U. Bogdahn Dr

Authors
  1. U. Bogdahn Dr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bogdahn, U. Chemosensitivity of malignant human brain tumors. J Neuro-Oncol 1, 149–166 (1983). https://doi.org/10.1007/BF00182961

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00182961

Keywords

Search

Navigation